Course description
The purpose of this course is to provide a comprehensive overview of next-generation cell and gene therapies and their potential to transform the treatment of cancer as well as other complex diseases. The participants will engage with the methods of cell and gene engineering through interactive toolbox sessions, facilitated in a flipped classroom format where students take the lead. Participants will gain an in-depth understanding of the principles and methods underlying cellular engineering, gene editing, and immunotherapy, while exploring how these technologies have evolved to address diverse medical challenges.
The course will examine current developments in the field, including CAR-T cells, tumor-infiltrating lymphocytes, gene-modified hematopoietic stem cells, and emerging in vivo gene editing strategies. Attention will also be given to considerations related to clinical translation, such as treatment resistance, safety, scalability, and regulatory aspects, while maintaining a broader perspective on scientific advances. Finally, the course will discuss future directions in cell and gene therapy, highlighting their role in shaping personalized medicine and expanding therapeutic opportunities across a wide range of difficult-to-treat diseases.
Prerequisites and Selection
Prerequisite courses, or equivalent
Knowledge and/or skills in Immunology, Molecular Biology or Cancer Biology, equivalent to course Basic Immunology or Tumor Immunology or corresponding courses.
Selection
Selection, within each category of applicants (selection category), will be based on:
1) the relevance of the course syllabus for the applicant’s individual study plan/research (according to written motivation).
2) start date of doctoral studies (priority given to earlier start date).
Course director
Arnika Wagner
Course syllabus
H7F6092
Department
Department of Medicine, Huddinge
Doctoral programme
Tumour Biology and Oncology (FoTO)
Type of course
**Other course
Keywords
cell therapy, gene therapy, CRISPR, CAR T cells